Please login to the form below

PCSK9 inhibitor

This page shows the latest PCSK9 inhibitor news and features for those working in and with pharma, biotech and healthcare.

Amarin files fish oil-based heart drug Vascepa in Europe

Other drugs including Amgen's injectable PCSK9 inhibitor Repatha (evolocumab) have achieved a similar level of efficacy in testing but Vascepa’s oral dosing, relatively low cost and absence of side

Latest news

Novartis acquires The Medicines Company for $9.7bn following takeover rumours

MedCo's PCSK9 inhibitor is a small, interfering RNA (siRNA) drug which works by blocking the synthesis of PCSK9 in the liver rather than targeting the protein itself.
TMC preps filings for inclisiran after final phase 3 trials hit the mark

filings and a market clash with other PCSK9 inhibitor drugs. ... Alnylam-partnered inclisiran is a small, interfering RNA (siRNA) drug which works by blocking the synthesis of PCSK9 in the liver rather than targeting the protein itself.
US court backs Sanofi/Regeneron in PCSK9 patent dispute with Amgen

patent rights to their PCSK9 inhibitor cholesterol drugs. ... Amgen filed a patent infringement complaint against Sanofi/Regeneron in 2014, claiming that their Praluent (alirocumab) PCSK9 inhibitor infringed on those patients.
Regeneron scores positive data in phase 3 cholesterol trial

Despite patients already taking lipid-lowering treatments, such as statins and PCSK9 inhibitors, their levels of cholesterol remained dangerously high prior to enrolment in the study. ... Regeneron and partner Sanofi have another approved
Amgen gets block on sales of Repatha rival in Germany

The lawsuit over the intellectual property for the PCSK9 inhibitor drugs dates back to 2016 when Amgen filed its patent infringement complaint shortly after Repatha was approved for marketing.

More from news
Approximately 11 fully matching, plus 44 partially matching documents found.

Latest Intelligence

Pharma deals during November 2014

AZ has been busy this month and in the deal with J&J, AZ will match its closely-watched PD-L1 checkpoint inhibitor MEDI4736 with Imbruvica. ... In July, BioMarin sold its PRV to Regeneron for $68m to expedite filing of its cholesterol drug, the PCSK9

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Principal Medical Writer: £48 - 58, 000 according to skills and experience benefits

Account Manager– Medical Communications: (Negotiable - depending on experience)

Senior Medical Writer, MedComms Agency: Salary TBC

Account Director or Senior Account Director: Salary TBC

Director of Scientific Services, Medical Communications, Six fig...: Six figure salary

Account Director, Medical Communications & Events: £50 - 65, 000 according to skills and experience benefits

Vice President: Competitive Salary Offered

Consultant: competitive salary

Subscribe to our email news alerts

PMHub

Add my company

Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

How do companies prepare for reimbursement?: Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
Integrating electronic health records into clinical trials: How organisations are working to realise the research potential of EHRs...
Keeping up the fight against HIV and using the lessons to tackle other threats: Danny Buckland interviews Gilead’s Mike Elliott...